Axogen, inc announces full launch of avive+ soft tissue matrix™

Alachua, fla. and tampa, fla., june 24, 2024 (globe newswire) -- axogen, inc. (nasdaq: axgn), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, avive+ soft tissue matrix™. avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. avive+ is processed and distributed in accordance with u.s. food and drug administration (fda) requirements for human cellular and tissue-based products (hct/p) under 21 cfr part 1271 regulations, u.s. state regulations as a 361 human tissue product.
AXGN Ratings Summary
AXGN Quant Ranking